The rapid evolution of life sciences and healthcare is set to redefine the risk landscape for insurance companies in the coming years. According to a new report by the Zurich Insurance Group, the increasing use of artificial intelligence (AI), precision medicine, and advanced treatments will pose new challenges to traditional insurance models. The report, titled "Beyond 2030: The Future of Life Sciences," examines the expected transformations in the healthcare and medical technology sectors and their impact on risk management and insurance liabilities.
AI is becoming a crucial element in drug discovery, treatment development, and medical data analysis. However, the transition of these technologies from the research and development phase to practical use creates a new set of risks. These risks include potential errors in models or data used, challenges related to protecting health data, cybersecurity, and regulatory compliance, which may lead to new insurance claims related to professional liability and technology.
The expansion of precision medicine and personalized treatments may improve healthcare outcomes but also changes the nature of risks that insurance companies need to assess. New products and treatments may require more detailed data to evaluate the likelihood of treatment success or complications, necessitating the development of new tools for underwriting and risk pricing.
The increasing complexity of the life sciences sector, with multiple parties involved, makes determining liability more difficult. This may lead to a greater need for insurance coverage for professional liability, product liability, and cyber risks, as well as business interruption and supply chain disruptions.
The life sciences sector is becoming more interconnected with geopolitical issues and supply chains, given its reliance on complex international networks for the production of medicines and medical technologies. Disruptions in manufacturing, transportation, or the availability of raw materials, data, and technology may impact sector companies and increase the demand for insurance solutions.
The report "Beyond 2030: The Future of Life Sciences" is based on interviews with 34 participants and a survey of 62 experts and specialists from within and outside the life sciences sector. Zurich Insurance believes that the competitive edge in the life sciences sector will depend not only on companies' ability to innovate new treatments but also on their capacity to manage the associated risks.
As the life sciences sector continues to evolve, insurance companies will need to adapt and develop new strategies to manage emerging risks. This may involve reevaluating risk pricing models, particularly when new technologies precede available historical data. The sector's future will be shaped by its ability to balance innovation with effective risk management.
Key points
- The increasing use of AI and precision medicine will pose new challenges to traditional insurance models.
- The life sciences sector is becoming more interconnected with geopolitical issues and supply chains.
- Insurance companies will need to adapt and develop new strategies to manage emerging risks in the life sciences sector.
